The Perimenopause Telehealth Boom: Medical Revolution or Marketing Machine?

A Personal Crisis, a Mountain, and a Revelation

Lisa Schrenk, a federal IT specialist in her early forties, was secretly planning her own funeral. She had been quietly setting aside belongings for friends, organizing her finances, and clearing out her office — all while suffering from treatment-resistant depression and mood disorders her doctors couldn't explain. It was only on a pre-dawn hike down Virginia's Old Rag Mountain, after overhearing fellow hikers swap stories about hormone therapy, that a possible answer emerged. She found Midi, a telehealth startup, through a Google search for "HRT-friendly doctors near me," sobbed through her first video appointment, and credits the resulting treatment with saving her life. She no longer hikes in secret despair — she hikes to recruit others to the cause.

Schrenk's story is increasingly common, and it sits at the center of one of the fastest-growing sectors in American healthcare: perimenopause telehealth. The industry has exploded, fueled by a convergence of regulatory change, venture capital, social media, and a generation of women who feel — often with real justification — that mainstream medicine has long ignored their symptoms.

The Numbers Behind the Boom

The scale of the expansion is striking. A SimilarWeb analysis found that four leading perimenopause startups — Midi, Winona, Alloy, and Evernow — saw a combined 490 percent increase in web traffic between 2023 and 2026. The potential customer base is enormous: more than 43 million American women are between the ages of 35 and 54, and perimenopause can begin years before a woman's last period, lasting for years afterward.

Midi has emerged as the sector's dominant player — dubbed the first "menopause unicorn" — and accepts health insurance, though not Medicare or Medicaid. Many competitors operate on a strictly cash-pay model, charging up to $200 per month for custom hormone formulations delivered as pills, patches, gels, or creams. The regulatory backdrop shifted dramatically when the FDA removed so-called "black box" warnings from hormone therapy last fall, reversing the chill that had been cast on prescribing since a flawed 2002 study led millions of women and their doctors to overestimate cancer risks. At the FDA announcement, Robert F. Kennedy Jr. framed the reversal as a victory for evidence-based medicine. At the same podium stood Alicia Jackson — founder of the perimenopause telehealth company Evernow, who had joined the Trump administration less than a month prior.

The regulatory shift has had immediate supply consequences. Estrogen patch shortages emerged shortly after the black-box warnings were lifted, and by June, progesterone supplies also tightened. Drug manufacturers, most of whom produce these off-patent medications with thin profit margins, were unprepared for the surge. The problem is compounding: new patients, many of whom are in their late thirties and forties rather than the traditional menopausal age range, tend to stay on hormones far longer than older patients, further pressuring supply chains.

The Symptom List Problem

At the heart of the boom lies a fundamental diagnostic challenge: there is no lab test that definitively confirms perimenopause. Clinicians diagnose it largely based on how patients describe feeling, against a backdrop of hormonal fluctuation that is, by definition, irregular and unpredictable. The symptom lists promoted by telehealth companies have grown extraordinarily broad. Midi, whose celebrity investor and spokesperson Amy Schumer rattles off a list in ads, claims there are more than 100 possible symptoms of menopause — including body odor, sensitive teeth, forgetfulness, bloating, asthma, and recurring urinary tract infections. Winona sells an estrogen-containing skincare product it claims reduces wrinkles.

Medical leaders in the field are openly alarmed. Stephanie Faubion, director of the Mayo Clinic's Center for Women's Health and medical director of the Menopause Society, says the perimenopause hype machine has gotten completely out of hand in its promotion of hormone therapy for longevity or general fatigue. Yale gynecologist Mary Jane Minkin, a longtime advocate for expanding patient awareness of hormone options, nonetheless worries that marketing is convincing women that anyone born before 2001 who occasionally feels tired must need these medications. Life stressors, she notes, are real — but that doesn't make them hormonal. The practical problem: a 38-year-old woman who sleeps badly might scroll her way to a perimenopause diagnosis and a hormone prescription. Statistically, she's probably not perimenopausal. But she might be. And Minkin concedes that for women without contraindications — no history of breast cancer, blood clots, or liver disease — the risks of taking hormones unnecessarily are probably low.

Venture Capital, Vending-Machine Medicine, and the Slippery Slope

The regulatory laxity governing telehealth has created a wide lane for operators with varying standards of care. Midi, which employs more than 550 medical professionals and requires mandatory continuing education, mandates actual virtual consultations. But a growing ecosystem of "turnkey" telehealth services lets almost anyone launch a hormone-prescribing platform within days. Some providers prescribe hormones "asynchronously" — patients fill out a questionnaire, a clinician approves it, and medication ships without any video visit. Midi's own clinical leadership dismisses these as "vending-machine prescriptions."

The financial pressures on venture-backed companies create their own risks. Midi has raised significant capital and is focused on growth over profitability, explicitly modeling itself on platform disruptors like Uber. Beyond hormone therapy, it now prescribes GLP-1 weight-loss medications and sells supplements and prescription skincare — product lines that draw sharp criticism. Prominent ob-gyn and author Jen Gunter has publicly called Midi's supplement and face cream sales predatory. The Mayo Clinic's Faubion flatly called estrogen face cream — which can cost $150 out of pocket for a three-month supply — "garbage," citing inadequate supporting data. Even Alicia Jackson, the Evernow founder now operating within HHS, acknowledges that bad actors are entering the space attracted by easy profits. Midi's former chief medical innovation officer, Heather Hirsch, now speaks skeptically of her previous employer, warning that venture capital pressure to deliver tenfold returns creates a slope that is, in her words, "slippery."

Midi itself got in trouble with the Better Business Bureau's National Advertising Division over a claim that 91 percent of patients find relief within two months — a figure it stopped using before formal action was taken. The company says it has internal review processes to keep advertising aligned with clinical data and that no clinician is incentivized to push any particular product.

A New Model for American Healthcare

The perimenopause telehealth surge is about more than hormones. It represents an accelerating shift toward a commercialized, consumer-driven model of medicine — one that runs in parallel with the rise of peptide clinics, at-home blood testing platforms, and concierge MRI startups. These platforms are not simply distributing conventional healthcare more efficiently; they are advancing a distinct philosophy in which patients self-identify conditions through social media, select treatments based on preference and marketing, and pay out of pocket for access that traditional insurance rarely covers.

Midi's CEO has described her ambition plainly: to build a national specialized primary care company for women, ultimately serving at least half the population. Whether that vision benefits patients or primarily benefits investors remains an open question — one that millions of women, navigating a healthcare system that has historically dismissed their symptoms, are answering for themselves, one prescription at a time.